Nundina › Discover calendars › FDA New Drug Approvals calendar › FDA approves Isembyld (apitegromab-mstn)FDA approves Isembyld (apitegromab-mstn)11 September 2026The FDA approved Isembyld (apitegromab-mstn), a biologic from Scholar Rock Inc. Form: Injectable, Injection. Granted priority review, reserved for treatments that would be a significant improvement over what exists. Application BLA761463.FDA New Drug Approvals calendarMore from this calendar

20 October 2026 - FDA approves Hibsago (bepirovirsen)

19 October 2026 - FDA approves Calrezdy (calcuim chloride)

19 October 2026 - FDA approves Cienby (sodium ctirate)

16 October 2026 - FDA approves Yulzety (rivaroxaban)

16 October 2026 - FDA approves Brytly (brytly (apraclonidine))